The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.
 
Sanjal Desai
No Relationships to Disclose
 
Michael Alexander Spinner
No Relationships to Disclose
 
Kevin A. David
No Relationships to Disclose
 
Veronika Bachanova
No Relationships to Disclose
 
Gaurav Goyal
No Relationships to Disclose
 
Raya Saba
No Relationships to Disclose
 
Kathleen Anne Dorritie
No Relationships to Disclose
 
Jacques Mario Azzi
No Relationships to Disclose
 
Elyse Harris
No Relationships to Disclose
 
Brendon Fusco
No Relationships to Disclose
 
Nuttavut Sumransub
No Relationships to Disclose
 
Haris Hatic
No Relationships to Disclose
 
Uroosa Ibrahim
No Relationships to Disclose
 
Siddharth Iyengar
No Relationships to Disclose
 
Katherine Cynthia Rappazzo
No Relationships to Disclose
 
Firas Baidoun
No Relationships to Disclose
 
Victor Manuel Orellana-Noia
Consulting or Advisory Role - ADC Therapeutics
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Catherine S. Magid Diefenbach
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Genentech/Roche; Janssen; Merck; MorphoSys; Seagen
Research Funding - Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); LAM Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Millennium (Inst); Roche/Genentech (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
Expert Testimony - Jim Harmon
 
Ranjana H. Advani
Consulting or Advisory Role - ADC Therapeutics; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; Epizyme; Genentech/Roche; Incyte; Karyopharm Therapeutics; Kura Oncology; Merck; Sanofi; Takeda
Research Funding - cyteir (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Janssen (Inst); Kura Oncology (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Ivana N. M. Micallef
No Relationships to Disclose